- Home
- AMST vs CHRO Comparison
AMST vs CHRO Comparison
Compare AMST & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMST
- CHRO
- Stock Information
- Founded
- AMST 2017
- CHRO 2002
- Country
- AMST United States
- CHRO United States
- Employees
- AMST N/A
- CHRO N/A
- Industry
- AMST Computer Software: Prepackaged Software
- CHRO
- Sector
- AMST Technology
- CHRO
- Exchange
- AMST Nasdaq
- CHRO Nasdaq
- Market Cap
- AMST 7.4M
- CHRO 8.1M
- IPO Year
- AMST 2020
- CHRO 2024
- Fundamental
- Price
- AMST $2.13
- CHRO $1.37
- Analyst Decision
- AMST
- CHRO Strong Buy
- Analyst Count
- AMST 0
- CHRO 1
- Target Price
- AMST N/A
- CHRO N/A
- AVG Volume (30 Days)
- AMST 56.4K
- CHRO 2.1M
- Earning Date
- AMST 05-09-2025
- CHRO 05-14-2025
- Dividend Yield
- AMST N/A
- CHRO N/A
- EPS Growth
- AMST N/A
- CHRO N/A
- EPS
- AMST N/A
- CHRO N/A
- Revenue
- AMST $86,115.00
- CHRO N/A
- Revenue This Year
- AMST N/A
- CHRO N/A
- Revenue Next Year
- AMST N/A
- CHRO N/A
- P/E Ratio
- AMST N/A
- CHRO N/A
- Revenue Growth
- AMST N/A
- CHRO N/A
- 52 Week Low
- AMST $2.00
- CHRO $0.45
- 52 Week High
- AMST $6.27
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- AMST 43.60
- CHRO 46.67
- Support Level
- AMST $2.00
- CHRO $1.29
- Resistance Level
- AMST $2.23
- CHRO $1.65
- Average True Range (ATR)
- AMST 0.19
- CHRO 0.20
- MACD
- AMST 0.01
- CHRO 0.02
- Stochastic Oscillator
- AMST 25.00
- CHRO 13.81
About AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.